Spelling suggestions: "subject:"viral vaccine""
11 |
Development of antibody and antigen detection assays and vaccines for SARS associated coronavirusWong, Hiu-ling, Beatrice., 黃曉靈. January 2007 (has links)
published_or_final_version / abstract / Microbiology / Doctoral / Doctor of Philosophy
|
12 |
Recombinant vaccines against infectious hematopoietic necrosis virus : bacterial systems for vaccine production and deliverySimon, Benjamin E. 09 October 2001 (has links)
Several systems were examined for the production and delivery of recombinant
vaccines for fish. C. crescentus was employed to produce a fragment of the IHNV
glycoprotein. When administered by injection to 0.5 gram rainbow trout (Oncorhynchus
mykiss), one of the fusion proteins (184 amino acids of the IHNV glycoprotein fused to
242 amino acids of the C-terminus of the Caulobacter crescentus) protected the fish
against lethal challenge with IHNV. Attenuated strains of Yersinia ruckeri were
generated using allelic exchange mutagenesis. These strains were characterized in terms
of in vitro growth characteristics and invasiveness. Attenuated E. coli and Y. ruckeri
were exploited to deliver plasmid DNA to fish cells in vitro; attenuated Y. ruckeri
bacteria were examined in vivo as bivalent vaccine delivery vehicles, either through the
expression of a fragment of the IHNV glycoprotein or by carrying a plasmid DNA
vaccine encoding the complete IHNV glycoprotein. A cell wall deficient strain
(11.29��dap) protected rainbow trout against lethal challenge with pathogenic Y. ruckeri.
Gene transfer to fish was not detected by luciferase reporter gene assays. No clear
protection from IHNV challenge was observed. / Graduation date: 2002
|
13 |
Development of antibody and antigen detection assays and vaccines for SARS associated coronavirusWong, Hiu-ling, Beatrice. January 2007 (has links)
Thesis (Ph. D.)--University of Hong Kong, 2008. / Also available in print.
|
14 |
Puumala hantavirus : immune responses and vaccines /Carvalho Nicacio, Cristina de, January 2002 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2002. / Härtill 5 uppsatser.
|
15 |
Concepts in DNA immunization : overcoming viral diversity and enhancing plasmid immunogenicity /Rollman, Erik, January 2004 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 6 uppsatser.
|
16 |
Interferon, virus vaccines and antiviral drugsRodrigues, Ana Mara Lopes January 2008 (has links)
The emergence of viruses with zoonotic potential, i.e. with the potential ability to cross species barriers to infect unnatural hosts, poses a huge threat to humans. It is therefore essential to develop new methodologies to rapidly and efficiently generate attenuated virus vaccine candidates to attempt to control the threat. Viruses need to be able to at least partially inhibit the host’s innate defence mechanism, known as the interferon (IFN) system, to replicate efficiently in vivo and establish a productive infection. It has been previously reported that viruses that have lost their ability to circumvent the host’s IFN response, or IFN-sensitive viruses, are promising candidates for live attenuated virus vaccines. Here we report on the development of a cell-based method to attempt to rapidly select IFN-sensitive viruses that can not block IFN signalling, from wild-type virus populations. Lentivirus vectors containing selection markers (HSV-tk – Herpes Simplex virus thymidine kinase gene and pac – puromycin resistance gene) under the control of a tight IFN-inducible promoter (the murine Mx1 promoter) were generated and used to specifically engineer HEp2 cell lines, termed Mx GIPSE and Mx TIPSE, for this purpose. The developed methodology relies on the engineered cell lines and a selection procedure using exogenous IFN-α and puromycin: if a cell is infected with IFN-resistant virus, it will die in the presence of IFN-α and puromycin because IFN signalling will be blocked, thereby blocking the activation of the Mx1 promoter and consequent expression of pac; if a cell is infected with an IFN-sensitive virus, it will survive in the presence of IFN-α and puromycin because the Mx1 promoter will become activated through the IFN signalling pathway, leading to the expression of pac. IFN-sensitive viruses can then be rescued from the surviving cells, and amplified using IFN-permissive cell lines expressing viral IFN antagonist proteins (proteins that block the host’s IFN response). When tested on PIV5 strains CPI- (an IFN-sensitive virus) and CPI+ (an IFN-resistant virus), the developed method allowed the survival and amplification of cells infected with CPI-, whilst cell death was observed for cells infected with CPI+. Whilst the developed methodology seems promising, further developments of the system are required. The possibilities of using the developed methodology in combination with other techniques, such as FACS sorting and immune selection, to rapidly select IFN-sensitive mutant viruses from wild-type and mutagenised virus populations are discussed. The potential to use Mx TIPSE cells to select IFN-resistant revertant viruses from IFN-sensitive virus populations is also discussed. In addition, a high throughput screening assay has been developed using the engineered Mx GIPSE and Mx TIPSE cell lines to search for compounds that block IFN signalling or that block the action of viral IFN antagonist proteins. Compounds that block IFN signalling would potentially be useful as anti-inflammatory drugs whilst compounds that block the action of viral IFN antagonist proteins would be valuable as antiviral drugs.
|
17 |
HIV and SIV specific cellular immunity in macaque models /Mäkitalo, Barbro, January 2003 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 5 uppsatser.
|
18 |
Hantaviruses : animal models, immunology and pathogenesis /Klingström, Jonas, January 2004 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 6 uppsatser.
|
19 |
Studies on polyomavirus virus-like particles - as vaccines and vectors for immune and gene therapy /Tegerstedt, Karin, January 2006 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2006. / Härtill 4 uppsatser.
|
20 |
Rift Valley fever development of diagnostics and vaccines /Näslund, Jonas, January 2010 (has links)
Diss. (sammanfattning) Umeå : Umeå universitet, 2010. / Härtill 4 uppsatser.
|
Page generated in 0.8836 seconds